September 17, 2014 6:59 AM ET

Healthcare Equipment and Supplies

Company Overview of Roka Bioscience, Inc.

Company Overview

Roka Bioscience, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the United States. It provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. It serves contract testing labs, food processors, and government agencies. The company was founded in 2009 ...

20 Independence Boulevard

4th Floor

Warren, NJ 07059

United States

Founded in 2009

121 Employees

Phone:

908-605-4700

Key Executives for Roka Bioscience, Inc.

Founder
Age: 58
Total Annual Compensation: $457.7K
Chief Financial Officer
Age: 57
Total Annual Compensation: $296.2K
Senior Vice President and General Manager
Age: 60
Total Annual Compensation: $296.2K
Compensation as of Fiscal Year 2013.

Roka Bioscience, Inc. Key Developments

Roka Bioscience, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Roka Bioscience, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. Net loss for the second quarter was $7.4 million, or a loss of $11.28 per share, compared with $7.9 million, or a loss of $15.96 per share, for the same period in 2013. Revenues for the quarter ended June 30, 2014 rose 107% to $1.4 million, from $671,000 in the same period in 2013. Loss from operations was $7,000,000 against $7,267,000 a year ago. Loss before income taxes was $7,337,000 against $7,941,000 a year ago. Net loss for the six months ended June 30, 2014 was $15.7 million, or a loss of $24.88 per share, compared with $15.7 million, or a loss of $34.10 per share, for the same period in 2013. Revenues for the six months ended June 30, 2014 rose 137% to $2.2 million, from $937,000 in the same period in 2013. The increased revenue in the quarter and six months resulted from an increase in the number of Atlas(R) instruments placed with commercial customers and increased commercial utilization of the Atlas(R) instruments. Loss from operations was $14,369,000 against 14,926,000 a year ago. Loss before income taxes was $15,699,000 against $15,655,000 a year ago.

Roka Bioscience, Inc. to Report Q2, 2014 Results on Aug 11, 2014

Roka Bioscience, Inc. announced that they will report Q2, 2014 results Pre-Market on Aug 11, 2014

Roka Bioscience, Inc., Q2 2014 Earnings Call, Aug 11, 2014

Roka Bioscience, Inc., Q2 2014 Earnings Call, Aug 11, 2014

Similar Private Companies By Industry

Company Name Region
Riley Medical, Inc. United States
Memory Dx, LLC United States
WeHealAnimals, Inc. United States
Hilsinger Holdings, Inc. United States
Medela, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 20, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Roka Bioscience, Inc., please visit www.rokabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.